<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-2016-2-177-182</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-1001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SHORT COMMUNICATIONS</subject></subj-group></article-categories><title-group><article-title>КОНЦЕНТРАЦИИ ИММУНОРЕГУЛЯТОРНЫХ БЕЛКОВ И НЕКОТОРЫХ ЦИТОКИНОВ В КРОВИ ЖЕНЩИН ПРИ ПРИЕМЕ МЕНОПАУЗАЛЬНОЙ ТЕРАПИИ</article-title><trans-title-group xml:lang="en"><trans-title>CONCENTRATIONS OF IMMUNOREGULATORY PROTEINS AND SOME CYTOKINES IN BLOOD OF WOMEN DURING MENOPAUSAL THERAPY</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зорина</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Zorina</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.б.н., главный научный сотрудник, научно-исследовательская лаборатория иммунологии,</p><p>654005, г. Новокузнецк, пр. Строителей, 5</p></bio><bio xml:lang="en"><p>PhD, MD (Biology), Main Research Associate, Research Laboratory of Immunology,</p><p>654005, Novokuznetsk, Stroiteley ave, 5</p></bio><email xlink:type="simple">macroglobulin@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Исакова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Isakova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ассистент кафедры акушерства и гинекологии,</p><p>г. Новокузнецк</p></bio><bio xml:lang="en"><p>Assistant Professor, Department of Obstetrics and Gynecology,</p><p>Novokuznetsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зорина</surname><given-names>Р. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Zorina</surname><given-names>R. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.б.н., ведущий научный сотрудник, научно-исследовательская лаборатория иммунологии,</p><p>г. Новокузнецк</p></bio><bio xml:lang="en"><p>PhD, MD (Biology), Leading Research Associate, Research Laboratory of Immunology,</p><p>Novokuznetsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баженова</surname><given-names>Л. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Bazhenova</surname><given-names>L. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, заведующая кафедрой акушерства и гинекологии,</p><p>г. Новокузнецк</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Head, Department of Obstetrics and Gynecology,</p><p>Novokuznetsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зорин</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zorin</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.б.н., профессор, заведующий научно- исследовательской лабораторией иммунологии,</p><p>г. Новокузнецк</p></bio><bio xml:lang="en"><p>hD, MD (Biology), Professor, Head, Research Laboratory of Immunology,</p><p>Novokuznetsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБОУ ДПО «Новокузнецкий государственный институт усовершенствования врачей» Министерства здравооохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novokuznetsk State Institute of Postgraduate Medicine, Ministry of Healthcare of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>15</day><month>04</month><year>2016</year></pub-date><volume>18</volume><issue>2</issue><fpage>177</fpage><lpage>182</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Зорина В.Н., Исакова О.В., Зорина Р.М., Баженова Л.Г., Зорин Н.А., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Зорина В.Н., Исакова О.В., Зорина Р.М., Баженова Л.Г., Зорин Н.А.</copyright-holder><copyright-holder xml:lang="en">Zorina V.N., Isakova O.V., Zorina R.M., Bazhenova L.G., Zorin N.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/1001">https://www.mimmun.ru/mimmun/article/view/1001</self-uri><abstract><p>Влияние препаратов менопаузальной гормональной и негормональной терапии на иммунный статус разнонаправленно, и зачастую результаты исследований противоречивы.</p><p>Цель работы состояла в комплексном изучении влияния препаратов менопаузальной гормональной и негормональной терапии на сывороточные показатели некоторых иммунорегуляторных белков (альфа2-макроглобулина – а2-МГ и ассоциированного с беременностью альфа2-гликопротеина – АБГ) и взаимосвязанных с ними цитокинов (IL-6, IL-8, TNFα, IFNγ, IL-2), а также VEGF.</p><p>При приеме менопаузальной гормональной и негормональной терапии выявлено снижение сывороточных уровней IL-6 вне зависимости от длительности приема и типа препарата. При динамическом наблюдении за женщинами, принимавшими менопаузальный гормональный препарат, содержащий 1 мг 17β-эстрадиола и 5 мг дидрогестерона, и негормональный препарат, содержащий генистеин в дозе 60 мг, в течение 3-6 месяцев, выявлено статистически значимое снижение уровней IL-8 в сыворотке крови. Уровень VEGF был подвержен значительной индивидуальной вариабельности. Концентрации иммунорегуляторного а2-МГ были стабильны при климактерическом синдроме и не отличались от здоровых, однако содержание АБГ, обладающего выраженными иммуносупрессивными свойствами, повышалось в 3-4 раза у 33-50% женщин, принимавших менопаузальный гормональный препарат, независимо от дозы гестагена (5 и 10 мг дидрогестерона) и от длительности его использования.</p><p>Полученные данные свидетельствуют о необходимости индивидуализации подбора препаратов для минимизации риска возникновения иммунодефицитных состояний на фоне приема менопаузальной гормональной терапии.</p></abstract><trans-abstract xml:lang="en"><p>It has been shown that the influence of hormonal and non-hormonal therapy of menopausal syndrome upon immune profile may be variable, and the results of appropriate studies may be often contradictory. The aim of this work was to investigate the influence of hormonal and non-hormonal therapy in menopausal syndrome upon serum levels of some immunoregulatory proteins, i.e., alpha2-macroglobulin (a2-MG), pregnancy-associated alpha 2-glycoprotein (PAG), contents of some related cytokines (IL-6, IL-8, TNFα, IFNγ, IL-2) as well as VEGF amounts. Administration of menopausal hormone treatment and nonhormonal therapy was associated with reduced IL-6 levels in serum, regardless of treatment duration, or type of drug applied. We have found a statistically significant decrease of IL-8 serum levels in the course of dynamic monitoring in the women taking a menopausal hormone preparation containing 1 mg of 17β-estradiol and 5 mg dydrogesterone, and a non-hormonal drug containing genistein (60 mg) for 3-6 months. The levels of VEGF demonstrated high individual variability during therapy of menopausal syndrome. Serum concentrations of immunoregulatory a2-MG were stable in climacteric syndrome, and did not differ from normal values. However, the content of PAG, a known immunosuppressive protein, was increased 3-4 times in serum of 33-50% of the women receiving menopausal hormonal therapy, regardless of progestogen dose (5 or 10 mg dydrogesterone), and duration of its use. These findings suggest a need for individualized drug selection in order to minimize a risk of immunodeficiency conditions in the patients receiving hormone therapy of menopausal syndrome.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>альфа-2-макроглобулин</kwd><kwd>ассоциированный с беременностью альфа-2-гликопротеин</kwd><kwd>VEGF</kwd><kwd>цитокин</kwd><kwd>менопаузальная гормональная терапия</kwd><kwd>генистеин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>alpha2-macroglobulin</kwd><kwd>pregnancy associated alpha-2-glycoprotein</kwd><kwd>VEGF</kwd><kwd>cytokines</kwd><kwd>menopausal hormonal therapy</kwd><kwd>genistein</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Зорин Н.А., Зорина В.Н., Зорина Р.М. Роль белков семейства макроглобулинов в регуляции опухолевого роста (Обзор литературы) // Онтогенез, 2006. Т. 37, № 1. C. 12-19. [Zorin N.A., Zorina V.N., Zorina R.M. Role of proteins of the macroglobulin family in regulation of tumor growth. Ontogenez = Ontogenesis, 2006, Vol. 37, no. 1, pp. 12-19. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Зорин Н.А., Зорина В.Н., Зорина Р.М. Роль белков семейства макроглобулинов в регуляции опухолевого роста (Обзор литературы) // Онтогенез, 2006. Т. 37, № 1. C. 12-19. [Zorin N.A., Zorina V.N., Zorina R.M. Role of proteins of the macroglobulin family in regulation of tumor growth. Ontogenez = Ontogenesis, 2006, Vol. 37, no. 1, pp. 12-19. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Зорина В.Н., Предеина Е.М., Зорина Р.М., Левченко В.Г., Баженова Л.Г., Зорин Н.А. Уровень ассоциированного с беременностью альфа-2-гликопротеина и гормональный фон при разных типах заместительной гормональной терапии климактерического синдрома // Клиническая лабораторная диагностика, 2007. № 7. C. 24-27. [Zorina V.N., Predeina E.M., Zorina R.M., Levchenko V.G., Bazhenova L.G., Zorin N.A. The level of pregnancy-associated alpha2-glycoprotein and the hormonal background during different options of hormonal replacement therapy in the menopausal syndrome. Klinicheskaya laboratornaya diagnostika = Clinical Laboratory Diagnostics, 2012, Vol. 7, pp. 24-27. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Зорина В.Н., Предеина Е.М., Зорина Р.М., Левченко В.Г., Баженова Л.Г., Зорин Н.А. Уровень ассоциированного с беременностью альфа-2-гликопротеина и гормональный фон при разных типах заместительной гормональной терапии климактерического синдрома // Клиническая лабораторная диагностика, 2007. № 7. C. 24-27. [Zorina V.N., Predeina E.M., Zorina R.M., Levchenko V.G., Bazhenova L.G., Zorin N.A. The level of pregnancy-associated alpha2-glycoprotein and the hormonal background during different options of hormonal replacement therapy in the menopausal syndrome. Klinicheskaya laboratornaya diagnostika = Clinical Laboratory Diagnostics, 2012, Vol. 7, pp. 24-27. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">De Medeiros A.R., Lamas A.Z., Caliman I.F., Dalpiaz P.L., Firmes L.B., de Abreu G.R., Moyses M.R., Lemos E.M., dos Reis A.M., Bissoli N.S. Tibolone has anti-inflammatory effects in estrogen-deficient female rats on the natriuretic peptide system and TNF-alpha. Regul. Pept., 2012, Vol. 10, no. 179 (1-3), pp. 55-60.</mixed-citation><mixed-citation xml:lang="en">De Medeiros A.R., Lamas A.Z., Caliman I.F., Dalpiaz P.L., Firmes L.B., de Abreu G.R., Moyses M.R., Lemos E.M., dos Reis A.M., Bissoli N.S. Tibolone has anti-inflammatory effects in estrogen-deficient female rats on the natriuretic peptide system and TNF-alpha. Regul. Pept., 2012, Vol. 10, no. 179 (1-3), pp. 55-60.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Edwards K.M., Mills P.J. Effect of estrogen versus estrogen and progesterone on cortisol and interleukin-6. Maturitas, 2008, Vol. 20, no. 61 (4), pp. 330-333.</mixed-citation><mixed-citation xml:lang="en">Edwards K.M., Mills P.J. Effect of estrogen versus estrogen and progesterone on cortisol and interleukin-6. Maturitas, 2008, Vol. 20, no. 61 (4), pp. 330-333.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Eilertsen A.L., Sandvik L., Steinsvik B., Sandset P.M. Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. J. Thromb. Haemost., 2008, Vol. 6, no. 6, pp. 928-934.</mixed-citation><mixed-citation xml:lang="en">Eilertsen A.L., Sandvik L., Steinsvik B., Sandset P.M. Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. J. Thromb. Haemost., 2008, Vol. 6, no. 6, pp. 928-934.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gomez C.R., Plackett T.P., Kovacs E.J. Aging and estrogen: modulation of inflammatory responses after injury. Exp. Gerontol., 2007, Vol. 42, no. 5, pp. 451-456.</mixed-citation><mixed-citation xml:lang="en">Gomez C.R., Plackett T.P., Kovacs E.J. Aging and estrogen: modulation of inflammatory responses after injury. Exp. Gerontol., 2007, Vol. 42, no. 5, pp. 451-456.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Grandas O.H., Mountain D.J., Kirkpatrick S.S., Rudrapatna V.S., Cassada D.C., Stevens S.L., Freeman M.B., Goldman M.H. Effect of hormones on matrix metalloproteinases gene regulation in human aortic smooth muscle cells. Surg Res., 2008, Vol. 148, no.1, pp. 94-99.</mixed-citation><mixed-citation xml:lang="en">Grandas O.H., Mountain D.J., Kirkpatrick S.S., Rudrapatna V.S., Cassada D.C., Stevens S.L., Freeman M.B., Goldman M.H. Effect of hormones on matrix metalloproteinases gene regulation in human aortic smooth muscle cells. Surg Res., 2008, Vol. 148, no.1, pp. 94-99.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lebovic D.I., Shifren J.L., Ryan I.P., Mueller M.D., Korn A.P., Darney P.D., Taylor R.N. Ovarian steroid and cytokine modulation of human endometrial angiogenesis. Hum. Reprod., 2000, Vol. 15, Suppl. 3, pp. 67-77.</mixed-citation><mixed-citation xml:lang="en">Lebovic D.I., Shifren J.L., Ryan I.P., Mueller M.D., Korn A.P., Darney P.D., Taylor R.N. Ovarian steroid and cytokine modulation of human endometrial angiogenesis. Hum. Reprod., 2000, Vol. 15, Suppl. 3, pp. 67-77.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Liu C.J., Kuo F.C., Hu H.M., Chen C.Y., Huang Y.B., Cheng K.H., Yokoyama K.K., Wu D.C., Hsieh S., Kuo C.H. 17β-Estradiol inhibition of IL-6-Scr and Cas and paxillin pathway suppresses human mesenchimal stem cells-mediated gastric cancer cell motility. Transl Res., 2014, Vol. 164, no. 3, pp. 232-243.</mixed-citation><mixed-citation xml:lang="en">Liu C.J., Kuo F.C., Hu H.M., Chen C.Y., Huang Y.B., Cheng K.H., Yokoyama K.K., Wu D.C., Hsieh S., Kuo C.H. 17β-Estradiol inhibition of IL-6-Scr and Cas and paxillin pathway suppresses human mesenchimal stem cells-mediated gastric cancer cell motility. Transl Res., 2014, Vol. 164, no. 3, pp. 232-243.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ma L.J., Guzman E.A., DeGuzman A., Muller H.K., Walker A.M., Owen L.B. Local cytokine levels associated with delayed-type hypersensitivity responses: modulation by gender, ovariectomy, and estrogen replacement. J. Endocrinol., 2007, Vol. 193, no. 2, pp. 291-297.</mixed-citation><mixed-citation xml:lang="en">Ma L.J., Guzman E.A., DeGuzman A., Muller H.K., Walker A.M., Owen L.B. Local cytokine levels associated with delayed-type hypersensitivity responses: modulation by gender, ovariectomy, and estrogen replacement. J. Endocrinol., 2007, Vol. 193, no. 2, pp. 291-297.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Pineda B., Garcia-Perez M.A., Vazguez F., Julia M.D., Tarin J.J., Hermenegildo C., Cano A. No effect of Cimicifuga racemosa extract on serum interleukin-6 levels and prostacyclin prodaction by human endothelial cells. Eur. J. Obstet. Gynecol. Reprod. Biol., 2009, Vol. 144, no. 1, pp. 93-94.</mixed-citation><mixed-citation xml:lang="en">Pineda B., Garcia-Perez M.A., Vazguez F., Julia M.D., Tarin J.J., Hermenegildo C., Cano A. No effect of Cimicifuga racemosa extract on serum interleukin-6 levels and prostacyclin prodaction by human endothelial cells. Eur. J. Obstet. Gynecol. Reprod. Biol., 2009, Vol. 144, no. 1, pp. 93-94.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tazhibi M., Dehghani M., Babazadeh S., Makkarian F., Tabatabaeian M., Sadeghi M., Rezaei P., Faghihi M. Hormonal and reproductive risk factors associated with breast cancer in Isfahan patients. J. Educ. Health Promot., 2014, Vol. 23, no. 3, p. 69.</mixed-citation><mixed-citation xml:lang="en">Tazhibi M., Dehghani M., Babazadeh S., Makkarian F., Tabatabaeian M., Sadeghi M., Rezaei P., Faghihi M. Hormonal and reproductive risk factors associated with breast cancer in Isfahan patients. J. Educ. Health Promot., 2014, Vol. 23, no. 3, p. 69.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Winsauer C., Kruglov A.A., Chashchina A.A., Drutskaya M.S., Nedospasov S.A. Cellular sources of pathogenic and protective TNF and experimental strategies based on utilization of TNF humanized mice. Cytokine Growth Factor Rev., 2014, Vol. 25, no. 2, pp. 115-123.</mixed-citation><mixed-citation xml:lang="en">Winsauer C., Kruglov A.A., Chashchina A.A., Drutskaya M.S., Nedospasov S.A. Cellular sources of pathogenic and protective TNF and experimental strategies based on utilization of TNF humanized mice. Cytokine Growth Factor Rev., 2014, Vol. 25, no. 2, pp. 115-123.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
